Welcure Drugs & Pharmaceuticals Ltd. has announced that its Board of Directors has approved a proposal from Telexcell Trade PTE LTD, Singapore, to acquire up to 25% equity stake in the company at ₹20 per share.
The Board has, however, ensured that Telexcell will not have any influence over Welcure’s management or decision-making process, preserving the company’s independence.
While Telexcell expressed interest in acquiring a substantial stake, it also sought some level of influence over the management of the company. The Board unanimously rejected this demand, ensuring that Welcure will remain independently managed by its existing board and professional team. Telexcell, like any other shareholder, may provide input, but no special rights will be granted to influence the company’s operations or governance.
The Board’s decision to uphold the company’s independence is a strategic move to maintain continuity of leadership and stability while aligning with the long-term interests of shareholders.
The Board outlined that Telexcell’s acquisition of shares will be through secondary transactions, ensuring no dilution of existing shareholder value and no liability for the company. These approved methods include:
These methods will ensure that Welcure's capital structure remains unchanged and no new shares are issued, safeguarding the interests of existing shareholders.
Welcure’s Board has made it clear that there are no plans for fundraising at this stage, including avenues like Preferential Allotment, QIP, or Private Placement. However, should the company require additional capital in the future, Telexcell will be given priority as a preferred partner, subject to regulatory approvals.
Read More: Best Pharma Stocks in October 2025 - Neuland Labs, Wockhardt & More – 5yr CAGR Basis!
The Board also highlighted that Telexcell’s willingness to invest at ₹20 per share, almost double the current market price of around ₹10, reflects a strong vote of confidence in Welcure’s intrinsic value. Shareholders can be reassured that the investment will not dilute their holdings, impose any liabilities, or affect the company’s management structure. This investment demonstrates global investor trust, without compromising the company’s independence.
Welcure’s Board reiterated its commitment to upholding the highest standards of corporate governance, ensuring full compliance with regulatory frameworks, and acting in the best interests of all stakeholders while pursuing long-term sustainable growth in the pharmaceutical sector.
On September 29, 2025, Welcure Drugs and Pharmaceuticals share price opened at ₹6.06 on BSE, near the previous close of ₹6.06. During the day, it surged to ₹6.19 and dipped to ₹5.80. The stock is trading at ₹5.90 as of 10:08 AM. The stock registered a decline of 2.64%.
Over the past week, it has declined by 16.31%, over the past month, it has declined by 36.22%, and over the past 3 months, it has declined by 56.62%.
Welcure Drugs & Pharmaceuticals Ltd. has welcomed Telexcell’s investment as a strategic foreign partner but has firmly ensured that no control rights are granted. This approach will balance investor confidence and the company’s independence, creating a mutually beneficial situation for all stakeholders.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Sep 29, 2025, 3:17 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
